MyFinsight
Home
Blog
About
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$61,033K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Inventory
Net income/(loss)
Others
Negative Cash Flow Breakdown
Accounts receivable
Accrued expenses and other liabi...
Prepaid and other current assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income/(loss)
18,656
-58,951
215,715
-42,151
Share-based compensation expense
25,173
21,246
28,186
27,197
Depreciation expense
291
327
339
446
Amortization of discounts for credit facility
-1,023
-
556
534
Amortization of discounts for credit facility and convertible notes
-
2,496
-
-
Amortization of discounts for convertible notes
-157
-
80
80
Accounts receivable
74,068
20,674
131,403
-21,118
Inventory
-18,806
8,658
-5,402
26,008
Prepaid assets
-
-
2,384
-7,953
Other current assets
-
-
-9,787
6,838
Prepaid and other current assets
11,270
8,087
-
-
Other assets
292
-120
4,440
-61
Right-of-use assets and lease liabilities
-16
-143
-113
215
Accounts payable
-7,741
18,195
-15,638
-1,045
Accrued expenses and other liabilities
-31,166
25,585
7,075
22,883
Other current liabilities
-
-
0
-
Other liabilities
-
-
-4,694
-
Net cash used in operating activities
-60,966
-14,176
108,468
4,445
Purchase of property and equipment
-
108
148
49
Net cash used in investing activities
-
-108
-148
-49
Proceeds from exercise of stock options
86
100
797
4,367
Proceeds from issuance of common stock under employee share purchase plan
-
1,159
0
2,191
Payments of employee tax withholding related to equity-based compensation
22
0
4
0
Net cash provided by financing activities
64
1,259
793
6,558
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-131
184
22
685
Net decrease in cash, cash equivalents and restricted cash
-61,033
-12,841
109,135
11,639
Cash, cash equivalents and restricted cash at beginning of period
467,760
359,827
359,827
359,827
Cash, cash equivalents and restricted cash at end of period
406,727
467,760
480,601
371,466
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$86K
(-69.40%↓ Y/Y)
Net cash provided by
financing activities
$64K
(-76.64%↓ Y/Y)
Canceled cashflow
$22K
Net decrease in
cash, cash...
-$61,033K
(-15.63%↓ Y/Y)
Canceled cashflow
$64K
Share-based compensation
expense
$25,173K
(-8.04%↓ Y/Y)
Inventory
-$18,806K
(-34.36%↓ Y/Y)
Net income/(loss)
$18,656K
(120.23%↑ Y/Y)
Depreciation expense
$291K
(-34.75%↓ Y/Y)
Payments of employee tax
withholding related to...
$22K
(214.29%↑ Y/Y)
Net cash used in
operating activities
-$60,966K
(-14.15%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$131K
(-136.49%↓ Y/Y)
Canceled cashflow
$62,926K
Accounts receivable
$74,068K
(349.56%↑ Y/Y)
Accrued expenses and
other liabilities
-$31,166K
(-3.35%↓ Y/Y)
Prepaid and other
current assets
$11,270K
Accounts payable
-$7,741K
(-146.32%↓ Y/Y)
Buy us a coffee